These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17925887)

  • 1. Tamibarotene.
    Miwako I; Kagechika H
    Drugs Today (Barc); 2007 Aug; 43(8):563-8. PubMed ID: 17925887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical experience with a new synthetic retinoid, tamibarotene (Am-80) for relapsed or refractory acute promyelocytic leukemia].
    Takeuchi M
    Gan To Kagaku Ryoho; 2006 Mar; 33(3):397-401. PubMed ID: 16531727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid.
    Tobita T; Takeshita A; Kitamura K; Ohnishi K; Yanagi M; Hiraoka A; Karasuno T; Takeuchi M; Miyawaki S; Ueda R; Naoe T; Ohno R
    Blood; 1997 Aug; 90(3):967-73. PubMed ID: 9242525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
    Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE
    Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamibarotene: AM 80, retinobenzoic acid, Tamibaro.
    Drugs R D; 2004; 5(6):359-62. PubMed ID: 15563242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80.
    Takeuchi M; Yano T; Omoto E; Takahashi K; Kibata M; Shudo K; Harada M; Ueda R; Ohno R
    Leuk Lymphoma; 1998 Nov; 31(5-6):441-51. PubMed ID: 9922035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
    Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamibarotene-induced low-grade reversible intravascular coagulation in a patient with acute promyelocytic leukemia.
    Ohata K; Yamazaki H; Asakura H; Shimadoi S; Nakao S
    Thromb Res; 2012 Feb; 129(2):213-4. PubMed ID: 21820159
    [No Abstract]   [Full Text] [Related]  

  • 9. Molecular remission in advanced acute promyelocytic leukaemia after treatment with the oral synthetic retinoid Tamibarotene.
    Di Veroli A; Ramadan SM; Divona M; Cudillo L; Giannì L; Wieland S; Giannotti F; Mirabile M; Arcese W; Lo-Coco F
    Br J Haematol; 2010 Oct; 151(1):99-101. PubMed ID: 20618325
    [No Abstract]   [Full Text] [Related]  

  • 10. All-trans retinoic acid and a novel synthetic retinoid tamibarotene (Am80) differentially regulate CD38 expression in human leukemia HL-60 cells: possible involvement of protein kinase C-delta.
    Uruno A; Noguchi N; Matsuda K; Nata K; Yoshikawa T; Chikamatsu Y; Kagechika H; Harigae H; Ito S; Okamoto H; Sugawara A
    J Leukoc Biol; 2011 Aug; 90(2):235-47. PubMed ID: 21393419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [State-of-the-art treatment of acute promyelocytic leukemia].
    Kiguchi T
    Rinsho Ketsueki; 2018; 59(10):2007-2018. PubMed ID: 30305503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A112, a tamibarotene dimethylaminoethyl ester, may inhibit human leukemia cell growth more potently than tamibarotene.
    Yuan C; Zhang YS; Cheng YN; Xue X; Xu WF; Qu XJ
    Leuk Lymphoma; 2012 Feb; 53(2):295-304. PubMed ID: 21846186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Retinoid therapy for autoimmune diseases].
    Fukasawa H; Kagechika H; Shudo K
    Nihon Rinsho Meneki Gakkai Kaishi; 2006 Jun; 29(3):114-26. PubMed ID: 16819260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study.
    Takeshita A; Asou N; Atsuta Y; Sakura T; Ueda Y; Sawa M; Dobashi N; Taniguchi Y; Suzuki R; Nakagawa M; Tamaki S; Hagihara M; Fujimaki K; Furumaki H; Obata Y; Fujita H; Yanada M; Maeda Y; Usui N; Kobayashi Y; Kiyoi H; Ohtake S; Matsumura I; Naoe T; Miyazaki Y;
    Leukemia; 2019 Feb; 33(2):358-370. PubMed ID: 30093681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-induction of complete remission with a new synthetic retinoid, Am-80, for relapse of acute promyelocytic leukaemia previously treated with all-trans retinoic acid.
    Takeuchi M; Yano T; Omoto E; Takahashi K; Kibata M; Shudo K; Ueda R; Ohno R; Harada M
    Br J Haematol; 1997 Apr; 97(1):137-40. PubMed ID: 9136955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan.
    Ohno R; Ohnishi K; Takeshita A; Tanimoto M; Murakami H; Kanamaru A; Asou N; Kobayashi T; Kuriyama K; Ohmoto E
    Leukemia; 1994; 8 Suppl 3():S64-9. PubMed ID: 7808028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term follow up of re-induction with a new synthetic retinoid, Am-80, for relapse of acute promyelocytic leukemia previously treated with all-trans retinoic acid: results of 7 cases from a single institute].
    Takeuchi M; Yoshida I; Takahashi K
    Rinsho Ketsueki; 2003 Nov; 44(11):1069-73. PubMed ID: 14689869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamibarotene: a candidate retinoid drug for Alzheimer's disease.
    Fukasawa H; Nakagomi M; Yamagata N; Katsuki H; Kawahara K; Kitaoka K; Miki T; Shudo K
    Biol Pharm Bull; 2012; 35(8):1206-12. PubMed ID: 22863914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiation syndrome in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene.
    DiNardo CD; Ky B; Vogl DT; Forfia P; Loren A; Luger S; Mato A; Tsai DE
    Med Oncol; 2008; 25(3):299-302. PubMed ID: 18181037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-adult T-cell leukemia effects of a novel synthetic retinoid, Am80 (Tamibarotene).
    Nakazato T; Okudaira T; Ishikawa C; Nakama S; Sawada S; Tomita M; Uchihara JN; Taira N; Masuda M; Tanaka Y; Ohshiro K; Takasu N; Mori N
    Cancer Sci; 2008 Nov; 99(11):2286-94. PubMed ID: 18771528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.